Author:
Al-Salama Zaina T.,Keating Gillian M.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–57.
2. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 (Suppl 3):iii49–56.
3. Grassi P, Verzoni E, Ratta R, et al. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. Drug Des Devel Ther. 2016;10:2167–72.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer (version 3.2016). 2016. http://www.nccn.org . Accessed 2 Nov 2016.
5. Malouf GG, Flippot R, Khayat D. Therapeutic strategies for patients with metastatic renal cell carcinoma in whom first-line vascular endothelial growth factor receptor-directed therapies fail. J Oncol Pract. 2016;12(5):412–20.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献